Top

Cancer Cell International

Published in:

Open Access 01-12-2021 | Colon Cancer | Primary Research

Prognostic value and immune infiltration of novel signatures in colon cancer microenvironment

Authors: Yilin Lin, Xiaoxian Pan, Zhihua Chen, Suyong Lin, Zhanlong Shen, Shaoqin Chen

Published in: Cancer Cell International | Issue 1/2021

Abstract

Background

Growing evidence has shown that the prognosis for colon cancer depends on changes in microenvironment. The purpose of this study was to elucidate the prognostic value of long noncoding RNAs (lncRNAs) related to immune microenvironment (IM) in colon cancer.

Methods

Single sample gene set enrichment analysis (ssGSEA) was used to identify the subtypes of colon cancer based on the immune genomes of 29 immune signatures. Cox regression analysis identified a lncRNA signatures associated with immune infiltration. The Tumor Immune Estimation Resource database was used to analyze immune cell content.

Results

Colon cancer samples were divided into three subtypes by unsupervised cluster analysis. Cox regression analysis identified an immune infiltration-related 5-lncRNA signature. This signature combined with clinical factors can effectively improve the predictive ability for the overall survival (OS) of colon cancer. At the same time, we found that the expression of H19 affects the content of B cells and macrophages in the microenvironment of colon cancer and affects the prognosis of colon cancer. Finally, we constructed the H19 regulatory network and further analyzed the possible mechanisms. We found that knocking down the expression of H19 can significantly inhibit the expression of CCND1 and VEGFA. At the same time, the immunohistochemical assay found that the expression of CCND1 and VEGFA protein was significantly positively correlated with the infiltration of M2 type macrophages.

Conclusion

The findings may help to formulate clinical strategies and understand the underlying mechanisms of H19 regulation. H19 may be a biomarker for targeted treatment of colon cancer.

Available only for authorised users

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.PubMed

Loeb LA, Kohrn BF, Loubet-Senear KJ, Dunn YJ, Ahn EH, O'Sullivan JN, Salk JJ, Bronner MP, Beckman RA. Extensive subclonal mutational diversity in human colorectal cancer and its significance. Proc Natl Acad Sci U S A. 2019.

Igarashi T, Shimizu K, Usui K, Yokobori T, Ohtaki Y, Nakazawa S, Obayashi K, Yajima T, Nobusawa S, Ohkawa T, et al. Significance of RAS mutations in pulmonary metastases of patients with colorectal cancer. Int J Clin Oncol. 2019. https://doi.org/10.1007/s10147-019-01582-z.CrossRefPubMed

Zhang Z, Li G, Qiu H, Yang J, Bu X, Zhu S, Zheng J, Dang C, Wang W, Chu D. The novel notch-induced long noncoding RNA LUNAR1 determines the proliferation and prognosis of colorectal cancer. Sci Rep. 2019;9(1):19915.CrossRefPubMedPubMedCentral

Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR, Winchester DP. The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017;67(2):93–9.CrossRefPubMed

Lai J, Chen B, Zhang G, Wang Y, Mok H, Wen L, Pan Z, Su F, Liao N. Identification of a novel microRNA recurrence-related signature and risk stratification system in breast cancer. Aging. 2019;11(18):7525–36.CrossRefPubMedPubMedCentral

Akinci D’Antonoli T, Farchione A, Lenkowicz J, Chiappetta M, Cicchetti G, Martino A, Ottavianelli A, Manfredi R, Margaritora S, Bonomo L, et al. CT radiomics signature of tumor and peritumoral lung parenchyma to predict nonsmall cell lung cancer postsurgical recurrence risk. Acad Radiol. 2019. https://doi.org/10.1016/j.acra.2019.05.019.CrossRefPubMed

Wang YQ, Zhang Y, Jiang W, Chen YP, Xu SY, Liu N, Zhao Y, Li L, Lei Y, Hong XH, et al. Development and validation of an immune checkpoint-based signature to predict prognosis in nasopharyngeal carcinoma using computational pathology analysis. J Immunother Cancer. 2019;7(1):298.CrossRefPubMedPubMedCentral

Liu S, Li S, Wang Y, Wang F, Zhang L, Xian S, Yang D, Yuan M, Dai F, Zhao X, et al. Prognostic value of infiltrating immune cells in clear cell renal cell carcinoma (ccRCC). J Cell Biochem. 2019. https://doi.org/10.1002/jcb.29479.CrossRefPubMedPubMedCentral

10.

Miao D, Margolis CA, Gao W, Voss MH, Li W, Martini DJ, Norton C, Bossé D, Wankowicz SM, Cullen D, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science (New York, NY). 2018;359(6377):801–6.CrossRef

11.

Job S, Rapoud D, Dos Santos A, Gonzalez P, Desterke C, Pascal G, Elarouci N, Ayadi M, Adam R, Azoulay D, et al. Identification of four immune subtypes characterized by distinct composition and functions of tumor microenvironment in intrahepatic cholangiocarcinoma. Hepatology (Baltimore, MD). 2019. https://doi.org/10.1002/hep.31092.CrossRef

12.

Hakimi AA, Voss MH, Kuo F, Sanchez A, Liu M, Nixon BG, Vuong L, Ostrovnaya I, Chen YB, Reuter V, et al. Transcriptomic profiling of the tumor microenvironment reveals distinct subgroups of clear cell renal cell cancer: data from a randomized phase III trial. Cancer Discov. 2019;9(4):510–25.CrossRefPubMedPubMedCentral

13.

Ghatalia P, Gordetsky J, Kuo F, Dulaimi E, Cai KQ, Devarajan K, Bae S, Naik G, Chan TA, Uzzo R, et al. Prognostic impact of immune gene expression signature and tumor infiltrating immune cells in localized clear cell renal cell carcinoma. J Immunother Cancer. 2019;7(1):139.CrossRefPubMedPubMedCentral

14.

Goldstein JB, Zhao L, Wang X, Ghelman Y, Overman MJ, Javle M, Shroff RT, Varadhachary GR, Wolf RA, McAllister F, et al. Germline DNA sequencing reveals novel mutations predictive of overall survival in a cohort of pancreatic cancer patients. Clin Cancer Res. 2019. https://doi.org/10.1158/1078-0432.CCR-19-0224.CrossRefPubMed

15.

Lahouel K, Younes L, Danilova L, Giardiello FM, Hruban RH, Groopman J, Kinzler KW, Vogelstein B, Geman D, Tomasetti C. Revisiting the tumorigenesis timeline with a data-driven generative model. Proc Natl Acad Sci U S A. 2019. https://doi.org/10.1073/pnas.1914589117.CrossRefPubMedPubMedCentral

16.

Seo SI, Do BJ, Kang JG, Kim HS, Jang MK, Kim HY, Shin WG. Helicobacter pylori eradication according to sequencing-based 23S ribosomal RNA point mutation associated with clarithromycin resistance. J Clin Med. 2019. https://doi.org/10.3390/jcm9010054.CrossRefPubMedPubMedCentral

17.

Jang HJ, Lee HS, Ramos D, Park IK, Kang CH, Burt BM, Kim YT. Transcriptome-based molecular subtyping of non-small cell lung cancer may predict response to immune checkpoint inhibitors. J Thorac Cardiovasc Surg. 2019. https://doi.org/10.1016/j.jtcvs.2019.10.123.CrossRefPubMed

18.

Niemira M, Collin F, Szalkowska A, Bielska A, Chwialkowska K, Reszec J, Niklinski J, Kwasniewski M, Kretowski A. Molecular signature of subtypes of non-small-cell lung cancer by large-scale transcriptional profiling: identification of key modules and genes by weighted gene co-expression network analysis (WGCNA). Cancers. 2019. https://doi.org/10.3390/cancers12010037.CrossRefPubMedPubMedCentral

19.

Geisler S, Coller J. RNA in unexpected places: long non-coding RNA functions in diverse cellular contexts. Nat Rev Mol Cell Biol. 2013;14(11):699–712.CrossRefPubMedPubMedCentral

20.

Liu X, Shao Y, Zhou J, Qian G, Ma Z. Nuclear factor kappaB signaling and its related non-coding RNAs in cancer therapy. Mol Therapy Nucleic Acids. 2019;19:208–17.CrossRefPubMed

21.

Vishnubalaji R, Shaath H, Elango R, Alajez NM. Noncoding RNAs as potential mediators of resistance to cancer immunotherapy. Semin Cancer Biol. 2019. https://doi.org/10.1016/j.semcancer.2019.11.006.CrossRefPubMed

22.

Xu M, Xu X, Pan B, Chen X, Lin K, Zeng K, Liu X, Xu T, Sun L, Qin J, et al. LncRNA SATB2-AS1 inhibits tumor metastasis and affects the tumor immune cell microenvironment in colorectal cancer by regulating SATB2. Mol Cancer. 2019;18(1):135.CrossRefPubMedPubMedCentral

23.

Wei C, Liang Q, Li X, Li H, Liu Y, Huang X, Chen X, Guo Y, Li J. Bioinformatics profiling utilized a nine immune-related long noncoding RNA signature as a prognostic target for pancreatic cancer. J Cell Biochem. 2019;120(9):14916–27.CrossRefPubMed

24.

Khadirnaikar S, Kumar P, Pandi SN, Malik R, Dhanasekaran SM, Shukla SK. Immune associated LncRNAs identify novel prognostic subtypes of renal clear cell carcinoma. Mol Carcinog. 2019;58(4):544–53.CrossRefPubMed

25.

Xin J, Li J, Feng Y, Wang L, Zhang Y, Yang R. Downregulation of long noncoding RNA HOTAIRM1 promotes monocyte/dendritic cell differentiation through competitively binding to endogenous miR-3960. Onco Targets Therapy. 2017;10:1307–15.CrossRef

26.

Huang D, Chen J, Yang L, Ouyang Q, Li J, Lao L, Zhao J, Liu J, Lu Y, Xing Y, et al. NKILA lncRNA promotes tumor immune evasion by sensitizing T cells to activation-induced cell death. Nat Immunol. 2018;19(10):1112–25.CrossRefPubMed

27.

Fang P, Xiang L, Chen W, Li S, Huang S, Li J, Zhuge L, Jin L, Feng W, Chen Y, et al. LncRNA GAS5 enhanced the killing effect of NK cell on liver cancer through regulating miR-544/RUNX3. Innate Immun. 2019;25(2):99–109.CrossRefPubMedPubMedCentral

28.

Gao Y, Sun W, Shang W, Li Y, Zhang D, Wang T, Zhang X, Zhang S, Zhang Y, Yang R. Lnc-C/EBPβ negatively regulates the suppressive function of myeloid-derived suppressor cells. Cancer Immunol Res. 2018;6(11):1352–63.CrossRefPubMed

29.

Atianand MK, Caffrey DR, Fitzgerald KA. Immunobiology of long noncoding RNAs. Annu Rev Immunol. 2017;35:177–98.CrossRefPubMedPubMedCentral

30.

Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF, Schinzel AC, Sandy P, Meylan E, Scholl C, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature. 2009;462(7269):108–12.CrossRefPubMedPubMedCentral

31.

Hanzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013;14:7.CrossRefPubMedPubMedCentral

32.

Wang W, Zhao Z, Yang F, Wang H, Wu F, Liang T, Yan X, Li J, Lan Q, Wang J, et al. An immune-related lncRNA signature for patients with anaplastic gliomas. J Neurooncol. 2018;136(2):263–71.CrossRefPubMed

33.

Yoshihara K, Shahmoradgoli M, Martinez E, Vegesna R, Kim H, Torres-Garcia W, Trevino V, Shen H, Laird PW, Levine DA, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612.CrossRefPubMed

34.

Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, Li B, Liu XS. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Can Res. 2017;77(21):e108–10.CrossRef

35.

Lin Y, Chen Z, Zheng Y, Liu Y, Gao J, Lin S, Chen S. MiR-506 Targets UHRF1 to inhibit colorectal cancer proliferation and invasion via the KISS1/PI3K/NF-κB signaling axis. Front Cell Dev Biol. 2019;7:266.CrossRefPubMedPubMedCentral

36.

Toyoshima Y, Kitamura H, Xiang H, Ohno Y, Homma S, Kawamura H, Takahashi N, Kamiyama T, Tanino M, Taketomi A. IL6 Modulates the immune status of the tumor microenvironment to facilitate metastatic colonization of colorectal cancer cells. Cancer Immunol Res. 2019;7(12):1944–57.CrossRefPubMed

37.

Peng D, Wang L, Li H, Cai C, Tan Y, Xu B, Le H. An immune infiltration signature to predict the overall survival of patients with colon cancer. IUBMB Life. 2019;71(11):1760–70.CrossRefPubMed

38.

Chen L, Pan X, Hu X, Zhang YH, Wang S, Huang T, Cai YD. Gene expression differences among different MSI statuses in colorectal cancer. Int J Cancer. 2018;143(7):1731–40.CrossRefPubMed

39.

Yan H, Deng X, Chen H, Cheng J, He J, Guan Q, Li M, Xie J, Xia J, Gu Y, et al. Identification of common and subtype-specific mutated sub-pathways for a cancer. Front Genet. 2019;10:1228.CrossRefPubMedPubMedCentral

40.

Caputo F, Santini C, Bardasi C, Cerma K, Casadei-Gardini A, Spallanzani A, Andrikou K, Cascinu S, Gelsomino F. BRAF-mutated colorectal cancer: clinical and molecular insights. Int J Mol Sci. 2019. https://doi.org/10.3390/ijms20215369.CrossRefPubMedPubMedCentral

41.

Hu X, Goswami S, Qiu J, Chen Q, Laverdure S, Sherman BT, Imamichi T. Profiles of long non-coding RNAs and mRNA expression in human macrophages regulated by interleukin-27. Int J Mol Sci. 2019. https://doi.org/10.3390/ijms20246207.CrossRefPubMedPubMedCentral

42.

Xu H, Jiang Y, Xu X, Su X, Liu Y, Ma Y, Zhao Y, Shen Z, Huang B, Cao X. Inducible degradation of lncRNA Sros1 promotes IFN-gamma-mediated activation of innate immune responses by stabilizing Stat1 mRNA. Nat Immunol. 2019;20(12):1621–30.CrossRefPubMed

43.

Xie Q, Chen S, Tian R, Huang X, Deng R, Xue B, Qin Y, Xu Y, Wang J, Guo M, et al. Long noncoding RNA ITPRIP-1 positively regulates the innate immune response through promotion of oligomerization and activation of MDA5. J Virol. 2018. https://doi.org/10.1128/JVI.00507-18.CrossRefPubMedPubMedCentral

44.

Nguyen VHL, Hough R, Bernaudo S, Peng C. Wnt/beta-catenin signalling in ovarian cancer: insights into its hyperactivation and function in tumorigenesis. J Ovarian Res. 2019;12(1):122.CrossRefPubMedPubMedCentral

45.

Lecarpentier Y, Schussler O, Hebert JL, Vallee A. Multiple targets of the canonical WNT/beta-catenin signaling in cancers. Front Oncol. 2019;9:1248.CrossRefPubMedPubMedCentral

46.

Weichhart T, Hengstschläger M, Linke M. Regulation of innate immune cell function by mTOR. Nat Rev Immunol. 2015;15(10):599–614.CrossRefPubMedPubMedCentral

47.

Kobayashi Y, Lim SO, Yamaguchi H. Oncogenic signaling pathways associated with immune evasion and the resistance to immune checkpoint inhibitors in cancer. Semin Cancer Biol. 2019. https://doi.org/10.1016/j.semcancer.2019.11.011.CrossRefPubMed

48.

Tartey S, Takeuchi O. Pathogen recognition and toll-like receptor targeted therapeutics in innate immune cells. Int Rev Immunol. 2017;36(2):57–73.CrossRefPubMed

49.

Lim KH, Staudt LM. Toll-like receptor signaling. Cold Spring Harbor Perspect Biol. 2013;5(1): 011247.CrossRef

50.

Li S, Hua Y, Jin J, Wang H, Du M, Zhu L, Chu H, Zhang Z, Wang M. Association of genetic variants in lncRNA H19 with risk of colorectal cancer in a Chinese population. Oncotarget. 2016;7(18):25470–7.CrossRefPubMedPubMedCentral

51.

Ding D, Li C, Zhao T, Li D, Yang L, Zhang B. LncRNA H19/miR-29b-3p/PGRN axis promoted epithelial-mesenchymal transition of colorectal cancer cells by acting on Wnt signaling. Mol Cells. 2018;41(5):423–35.PubMedPubMedCentral

52.

Snider J, Hanif A, Lee ME, Jin K, Yu AR, Graham C, Chuk M, Damjanovic D, Wierzbicka M, Tang P, et al. Mapping the functional yeast ABC transporter interactome. Nat Chem Biol. 2013;9(9):565–72.CrossRefPubMedPubMedCentral

53.

Wang M, Han D, Yuan Z, Hu H, Zhao Z, Yang R, Jin Y, Zou C, Chen Y, Wang G, et al. Long non-coding RNA H19 confers 5-Fu resistance in colorectal cancer by promoting SIRT1-mediated autophagy. Cell Death Dis. 2018;9(12):1149.CrossRefPubMedPubMedCentral

54.

Chen S, Bu D, Ma Y, Zhu J, Chen G, Sun L, Zuo S, Li T, Pan Y, Wang X, et al. H19 overexpression induces resistance to 1,25(OH)2D3 by targeting VDR through miR-675-5p in colon cancer cells. Neoplasia (New York, NY). 2017;19(3):226–36.CrossRef

Title: Prognostic value and immune infiltration of novel signatures in colon cancer microenvironment
Authors: Yilin Lin
Xiaoxian Pan
Zhihua Chen
Suyong Lin
Zhanlong Shen
Shaoqin Chen
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Colon Cancer
Colon Cancer
Published in: Cancer Cell International / Issue 1/2021
Electronic ISSN: 1475-2867
DOI: https://doi.org/10.1186/s12935-021-02342-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2021

Absence of EpCAM in cervical cancer cells is involved in slug induced epithelial-mesenchymal transition

Silencing of the lncRNA H19 enhances sensitivity to X-ray and carbon-ions through the miR-130a-3p /WNK3 signaling axis in NSCLC cells

RHBDF2 gene functions are correlated to facilitated renal clear cell carcinoma progression

Circular RNAs and their role in renal cell carcinoma: a current perspective

Correction to: Dynamic serum biomarkers to predict the efficacy of PD-1 in patients with nasopharyngeal carcinoma

LncRNA ASAP1-IT1 enhances cancer cell stemness via regulating miR-509-3p/YAP1 axis in NSCLC

Keynote webinar | Spotlight on antibody–drug conjugates in cancer